Pharmacokinetics of Intranasal Ketorolac in Children

NCT02297906 Phase 1 TERMINATED

Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that is typically given to both adults and children by the intravenous (IV) or intramuscular (IM) route for analgesic purposes. Ketorolac can also be given by the intranasal (IN) route using a mucosal atomization device (MAD). We aim to study the pharmacokinetics of ketorolac when administered by the IN route using the MAD.

Details

Lead sponsor	Columbia University
Phase	Phase 1
Status	TERMINATED
Enrolment	18
Start date	2015-02
Completion	2017-11-29

Conditions

• Evaluating Pharmacokinetics of Intranasal Ketorolac
• Pain

Interventions

• Ketorolac

Primary outcomes

• Cmax of intranasal ketorolac — 60 minutes
  Maximum serum concentration of ketorolac, after intranasal administration

Countries

United States